Study record · Retatrutide
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Dose-dependent weight reduction; highest-dose groups produced very large mean reductions over 48 weeks.
Key result
Dose-dependent weight reduction; highest-dose groups produced very large mean reductions over 48 weeks.
Study details
Study designRandomized, double-blind, placebo-controlled dose-ranging trial
PhasePhase 2
PopulationAdults with obesity or overweight plus a weight-related condition
Sample size338
RouteSubcutaneous
Regimen / exposureOnce weekly 1, 4, 8 or 12 mg arms with protocol-defined starting doses
Duration48 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change
Safety resultGI events were common; heart rate increased dose-dependently.
Key limitationsPhase 2 duration; investigational product; no long-term outcomes; cross-trial comparisons are inappropriate.
Registry / identifierNCT04881760